Biogen Idec’s ALS drug Failed Final Clinical Trial

.

Biogen Idec’s ALS drug Failed Final Clinical Trial

As per reports, it has been recently revealed that Biogen Idec was unable to get through the last clinical trial of its ALS drug. Researchers have acknowledged the loss by saying that it was not only shocking but discouraging as well.

Dr. Robert Brown, who is an ALS researcher, was of the view that they have worked hard on the drug, but they failed a crucial test. However, this does not mean that no more research will take as the disease needs an effective treatment.

While talking about the last and final clinical trial, which could not attain success, Brown said that they had enrolled 943 people, who were suffering from amyotrophic lateral sclerosis. They were enrolled to test the efficacy of their once-promising dexpramipexole drug.

After carrying out the study, Brown said that they did not find any sort of benefit from the drug. And, then only, they decided to halt the programme. "While these results were not what we expected, we hope this data will provide a foundation for future ALS research", said Dr. Douglas Kerr, who is the director of neurodegeneration clinical research at Biogen.

The failure does not mark an end to the research, said Kerr, as they still have been working on it.

 


Latest News

Apple sued by iPhone 6 and iPhone 6 Plus owners affected by ‘Touch Disease’ prob
Apple Watch 2 expected to come with some noteworthy new features
Facebook’s ‘Trending’ section is getting a makeover
Google adds two popular games -- Solitaire and Tic-tac-toe -- to Search
HP Inc. posts better than expected financial results for its fiscal Q3
Tesla announces new Model S and X versions with upgraded battery, super fast acc
Google announces the launch of Android 7.0 ‘Nougat’
Lyft seeking $9B buyout, Uber not willing to pay more than $2B
Recode: Lyft had recently sought $9B in buyout offer
Uber signs $300M deal with Volvo; acquires startup Otto
Instagram introduces new ‘Event Channel’ feature
Ford plans to build a fleet of fully autonomous vehicle by 2021